No data to show
XNAS
BDTX
Market cap160mUSD
Jul 30, Last price
2.82USD
1D
1.44%
1Q
65.88%
IPO
-92.48%
Name
Black Diamond Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.91%
Rev. gr., 5y
%
Revenues
0k
Net income
-70m
L-15.48%
CFO
-62m
L-6.62%
Earnings
Aug 04, 2025
Profile
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO date
Jan 30, 2020
Employees
65
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 78,781 | 86,897 | 96,066 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (78,781) | (86,897) | (96,066) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (4,399) | |||||||
Tax Rate | ||||||||
NOPAT | (78,781) | (86,897) | (91,667) | |||||
Net income | (69,676) -15.48% | (82,442) -2.46% | (84,520) -31.40% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 24,494 | 71,850 | 177 | |||||
BB yield | -20.80% | -58.17% | -0.27% | |||||
| Debt | ||||||||
Debt current | 3,113 | 2,841 | ||||||
Long-term debt | 37,564 | 44,370 | 53,439 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (61,011) | (83,917) | (67,695) | |||||
| Cash flow | ||||||||
Cash from operating activities | (62,303) | (66,717) | (85,082) | |||||
CAPEX | (33) | (192) | ||||||
Cash from investing activities | 16,968 | 16,346 | 53,366 | |||||
Cash from financing activities | 25,547 | 71,932 | 177 | |||||
FCF | (75,467) | (83,226) | (88,308) | |||||
| Balance | ||||||||
Cash | 98,575 | 131,400 | 122,807 | |||||
Long term investments | 1,168 | |||||||
Excess cash | 98,575 | 131,400 | 123,975 | |||||
Stockholders' equity | (487,076) | (417,451) | (336,808) | |||||
Invested Capital | 589,143 | 559,485 | 29,959 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 55,028 | 43,955 | 36,326 | |||||
Price | 2.14 -23.84% | 2.81 56.11% | 1.80 -66.23% | |||||
Market cap | 117,761 -4.66% | 123,513 88.90% | 65,386 -66.10% | |||||
EV | 56,750 | 39,596 | (2,309) | |||||
EBITDA | (78,438) | (86,460) | (95,558) | |||||
EV/EBITDA | 0.02 | |||||||
Interest | 3,909 | |||||||
Interest/NOPBT | ||||||||